Merck fails, and the "third wave" of BTK inhibitors surges

Breaking the Cocoon Bio

2026.11.20 18:23

· From Shanxi

Full text 4640 words

Text | CocoonBio

On November 17, 2026, Merck announced the termination of all BELLWAVE Phase III projects for the non-covalent BTK inhibitor Nemtabrutinib. The rationale given by the external data monitoring committee was that the benefits may not be sufficient to outweigh the risks. Seven years ago, Merck paid about $2.7 billion for the company behind the drug. Seven years later, the clinical phase III failed and the pipeline came to an end.

Just by looking at this news, it is easy to read a signal of "frustration of the non-covalent route". But if we zoom out, Merck’s exit is not the ebb of the third wave, but a sign that the wave has entered deep water.

The story of BTK inhibitors is a typical history of modern pharmaceutical iterations. It did not stay in the romantic narrative of "the first drug changed the disease", but was pushed forward by three clear waves: in the first round, covalent BTK inhibitors proved that this target can subvert the treatment of hematoma; in the second round, the second generation of drugs represented by zanubrutinib Covalent inhibitors have completed the intergenerational replacement of first-generation molecules with "head-to-head superiority"; in the third round, non-covalent inhibitors entered the scene with the mission of "overcoming C481S resistance", trying to build on the success of covalent drugs and answer a question that covalent drugs themselves cannot answer.

Each wave is the product of new problems created by the success of the previous wave.

The First Wave: Target’s “Proof Moment”

BTK, as a drug target, was always in the dark before ibrutinib was launched. Although the centrality of B-cell receptor signaling pathways in B-cell malignancies has long been recognized, turning the idea of ​​a kinase inhibitor into a usable oral drug took far longer than expected.

The turning point occurred in 2013. In November of this year, ibrutinib was approved by the FDA and became the world's first BTK inhibitor. It was jointly developed by Pharmacyclics and Janssen, a subsidiary of Johnson & Johnson. Its approval itself is symbolic enough, but what really turned ibrutinib from a "new drug" into a "gold standard" was the subsequent RESONATE study.

In patients with relapsed/refractory CLL, ibrutinib was compared head-to-head with the then “gold standard” ofatumumab. At 6 years of follow-up, the median progression-free survival in the ibrutinib group was 44.1 months, while that in the ofatumumab group was only 8.1 months. The risk of disease progression or death was reduced by approximately 85%.

In the history of CLL treatment, it is rare that an oral small molecule drug can provide a survival benefit of this magnitude in a phase III randomized study. Some hematology experts directly described ibrutinib as a "turning point" in the treatment of CLL at the time. Subsequently, the RESONATE-2 study confirmed its superiority over chlorambucil in elderly patients with newly treated CLL, further pushing BTK inhibitors to the first-line treatment table.

Business data is the most straightforward footnote to this “proof”. The global commercialization of ibrutinib started in 2014, reaching US$3.083 billion in 2016, and peaked at approximately US$9.78 billion in 2021, once becoming the fourth best-selling anti-cancer drug in the world. One target, one molecule, has supported a market approaching tens of billions of dollars in less than ten years - this is the wealth left by the first wave.

But the success of the first wave itself planted the seeds for the next iteration. The covalent binding mechanism of ibrutinib determines that it must form an irreversible chemical bond with the C481 site of the BTK protein, and the selectivity of covalent drugs is naturally limited. Adverse reactions such as bleeding, atrial fibrillation, and hypertension caused by off-target inhibition of TEC, EGFR, ITK and other kinases, as well as drug resistance caused by C481S mutation after long-term medication, have gradually accumulated into a clinical burden that cannot be ignored in the real world.

The first generation of drugs proved that this target was worth pursuing, but it did not prove that it was the "final answer" for this target.

The second wave: The rise of zanubrutinib

If the achievement of ibrutinib is “from 0 to 1”, then the core proposition of the second wave is “from First to Best”. This "Best" cannot be based on slogans, it must be presented in a head-on collision with the first-generation drugs.

It is with this mission that zanubrutinib enters the battlefield. As a second-generation covalent BTK inhibitor, its design logic is not mysterious: through optimization of the molecular structure, off-target binding to non-BTK kinases is reduced, and while retaining C481 covalent inhibition, the selectivity is pushed to a higher level. But the selective advantage was easily seen as a nice-to-have in the early days—until the ALPINE study produced head-to-head data.

ALPINE was one of the few phase III studies in the field of BTK inhibitors that directly compared ibrutinib. At a median follow-up of 42.5 months, the PFS hazard ratio of zanubrutinib versus ibrutinib was 0.68; in the subgroup with the worst prognosis, the del(17p)/TP53 mutation, the hazard ratio further dropped to 0.51. This means that zanubrutinib not only delays disease progression in the overall population, but also has more prominent advantages in the traditionally most difficult-to-treat group of patients.

The gap in safety is also clear: in the ALPINE study, the incidence of atrial fibrillation/atrial flutter was 7.1% in the zanubrutinib group and 17.0% in the ibrutinib group; no cardiac death was reported in the zanubrutinib group, while there were 6 cases in the ibrutinib group. In the field of BTK inhibitors, which require long-term or even lifelong medication, the combination of "better efficacy" and "better cardiac safety" does not constitute a marginal improvement, but a redrawing of treatment standards.

This time, the market also voted with sales. Zanubrutinib started from US$40 million in 2020, exceeded US$1 billion in 2023, reached US$2.644 billion in 2024, and further surged to US$3.93 billion in 2025; during the same period, ibrutinib fell from US$9.777 billion to US$5.692 billion. In the second quarter of 2026, the single-quarter sales of zanubrutinib ranked first among all BTK inhibitors, completing a true "intergenerational switch." In the third quarter of 2026, its single-quarter sales reached US$1.391 billion, a year-on-year increase of 34%.

The core driving force behind the status of zanubrutinib as a global drug is that in a huge market that has been fully educated by first-generation drugs, it is the first molecule to use randomized phase III head-to-head data to prove that it is "better than existing standards in both efficacy and safety dimensions." The completion of the second wave marks the transition of BTK inhibitors from the stage of "available drugs" to the stage of "clear ranking among good drugs".

But the second wave did not solve a fundamental problem: zanubrutinib is still a covalent inhibitor and still relies on the C481 site. When patients develop the C481S mutation after treatment with zanubrutinib, the covalent binding fails and the disease will still progress. The second wave pushed the potential of covalent BTK inhibitors near its limits, but it was precisely at this limit that the third wave gained its historical legitimacy.

The third wave: non-covalent “dimensionality enhancement”

The logic behind the emergence of non-covalent BTK inhibitors has not been a "competition of efficacy" from the beginning, but "answering questions that cannot be answered by covalent drugs."

The C481S mutation prevents covalent drugs from forming irreversible bonds, while non-covalent inhibitors do not rely on the C481 site and inhibit both wild-type and C481S mutant BTK in a reversible hydrogen bonding manner, mechanistically bypassing the core pathway of covalent resistance. The initial positioning of the third wave: to provide a follow-up option that remains on the BTK target for patients who progress after treatment with covalent BTK inhibitors.

Eli Lilly's pitubrutinib (Jaypirca) is the first molecule to hit the line on this path. In 2023, it received accelerated approval for relapsed/refractory mantle cell lymphoma previously treated with BTK inhibitors; in December 2025, the FDA further approved it for relapsed/refractory CLL/SLL previously treated with covalent BTK inhibitors, and converted accelerated approval to traditional approval. Commercially, pitubrutinib's annual sales in 2025 will be approximately US$506 million. The absolute value is not comparable to zanubrutinib or ibrutinib, but the year-on-year growth rate of about 51% shows that the needs of the drug-resistant population are real and are being fulfilled.

What really gives the third wave the meaning of “dimensionality enhancement” is the BRUIN CLL-314 research. This is the first randomized phase III trial to directly compare non-covalent versus covalent BTK inhibitors. Among CLL/SLL patients who were untreated or not treated with BTK inhibitors, the objective response rate was 87.0% for pitubrutinib and 78.5% for ibrutinib; the incidence rates of atrial fibrillation/atrial flutter were 2.4% and 13.5% respectively. In an analysis with immature data, the risk of disease progression or death in the untreated subgroup was numerically reduced by 76%, and formal superiority testing has yet to be followed up. These data comparisons have shown that non-covalent BTK inhibitors also have the ability to subvert the first generation of BTK covalent inhibitors.

But the complexity of this path is also exposed at this time. The failure of Merck's Nemtabrutinib illustrates that the non-covalent mechanism itself does not constitute an automatic clinical advantage. BELLWAVE-011 is a Phase III study directly comparing ibrutinib or acotinib in patients with previously untreated CLL/SLL. The eDMC determined during the interim review that the benefits were insufficient to offset the risks, and the entire project was terminated.

In a competitive landscape where covalent drugs with "both excellent efficacy and safety" such as zanubrutinib already occupy the front line, and pitubrutinib has established a bridgehead in the back line, if latecomers cannot provide enough data to distinguish themselves from existing non-covalent molecules in the resistance window or in the treatment-naïve population, the simple "non-covalent" label is no longer a pass.

The player landscape of the current third wave therefore shows obvious stratification.

Eli Lilly's pitubrutinib is the only non-covalent BTK inhibitor approved for marketing and is in a leading position in indication expansion and first-line exploration. Merck's Nemtabrutinib exited Phase III, becoming the most costly warning on this path.

In the follow-up echelon, Chi-Med's HMPL-760 has entered the late-stage research and development stage of hematoma, and has chosen a more aggressive direction, relapsed/refractory diffuse large B-cell lymphoma (DLBCL), which is a restricted area of ​​indication that BTK inhibitors have never really conquered before; domestic players such as Dizhe Pharmaceuticals, Hansoh Pharmaceuticals, and Lupeng Pharmaceuticals are also eyeing BTK non-covalent inhibitors.

The third wave is far from the end, but its competition dimension has shifted from the basic question of "whether there are any" BTK non-covalent inhibitors to the specific layout of drug indications.

direction of tide

Looking back at the three waves of BTK inhibitors, a clear identification clue runs through them.

The first wave addressed “whether the target is established.” With RESONATE and peak sales of nearly 10 billion US dollars, ibrutinib gave an unquestionable affirmative answer. But its success has created two new problems at the same time: the safety burden caused by off-target toxicity, and the drug resistance caused by the C481S mutation.

The second wave used zanubrutinib's ALPINE head-to-head data to answer the first question - through selectivity optimization, the efficacy and safety were simultaneously pushed to a level superior to the first-generation drug within the covalent mechanism, completing intergenerational replacement. But it cannot answer the second question because C481S resistance is the boundary of the covalent mechanism itself.

The third wave is unfolding along this boundary: non-covalent inhibitors use a binding method that does not rely on C481, trying to extend the life cycle of BTK targets after the failure of covalent drugs, and further impact on first-line treatment.

Merck's discontinuation of Nemtabrutinib should not be read as a failure of the third wave. It is more like a natural screening after a mature target enters the deep water area: when covalent BTK inhibitors have provided a good enough baseline treatment, and when a leader in the non-covalent track has established preliminary barriers with randomized phase III data, it is difficult for latecomers to pass phase III trials based on conventional benefit-risk ratios based only on molecules with "same mechanism and same positioning". The tide isn’t receding, it’s simply weeding out players that don’t bring real differentiated clinical value.

The sense of history of BTK inhibitors lies precisely in the fact that it shows how a target is "opened" by three generations of drugs in sequence: the first generation proved that it is worth doing, the second generation proved that it can do better, and the third generation is trying to prove that even where the first two generations of drugs have been successful, there are still unanswered clinical questions.

Each wave is not a denial of the previous one, but is pushed forward by new problems created by the previous success. For those who make drugs, this may be a part worth remembering more than any single molecule sales: the real and lasting value of a target does not lie in how successful the first drug is, but in whether the latecomers still have unfinished business worth pursuing.

Respect for the original work, if you are qualified, you should be appreciated.

According to the real-name requirement of the Cybersecurity Law, please bind your mobile phone number before posting a comment.

Express

10:21

It is reported on the Internet that the trunk of Leipao A10 was crushed by several boxes of beer. Leapao responded.

10:19

International gold prices continue to decline

10:16

Federal Reserve official Paulson: Supports prudent interest rate hikes and can continue to raise interest rates if necessary

10:15

If the sale to SoftBank cannot be completed, ABB is reported to be considering spinning off its robotics business.

10:12

Anthropic IPO received approximately US$115 billion to US$120 billion in subscription demand from retail investors

10:10

The price of gold jewelry continues to fall, with Lao Fengxiang falling by 34 yuan in a single day

Food delivery company Wonder is considering selling Grubhub

10:09

Databricks is reported to be negotiating a new round of financing, with a valuation expected to reach US$225 billion

10:08

CrowdStrike reportedly in talks to acquire cybersecurity company Zscaler

10:06

Apollo and Goldman Sachs complete pricing of $44 billion SpaceX GPU financing

‘Big Short’ investor Michael Burry reduces holdings of Nvidia put options, locking in some gains

10:04

"Grand Theft Auto 6" retail sales hit $3.79 billion on first day, setting entertainment industry record

09:59

Iran's Foreign Minister: The "two-day plan" is still on the table and is willing to discuss it with the United States

09:53

Trump: China-Russia-US presidents’ meeting “unprecedented” and “of great significance”

09:45

China has 27,000 "5G + Industrial Internet" projects, covering all 41 major industrial categories

09:44

The Security Council holds the ninth round of intention-to-hold votes on the selection of the next United Nations Secretary-General

09:39

France strengthens online supervision of 2027 presidential election

09:31

The S&P 500 fell for the seventh consecutive trading day, setting its longest losing streak since 2020.

09:28

Oracle said it has raised all the funds needed to fulfill its contract with OpenAI and expects free cash flow to exceed US$30 billion in fiscal 2029

09:27

The Nasdaq 100 index closed down 5.6%, wiping out $2.1 trillion in market value, erasing its gains this year.

Scan to download App